Telix Pharmaceuticals Limited
TLX
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.7B
$11.44
▲ +5.42%
P/E
—
Mkt Cap
$3.7B
52-Wk Range
$6.28–$12.48
52-Week Range
$6.28 - $12.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 15.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.6).
- Extreme premium - high expectations embedded
Growth
Stable outlook
Value
Extreme premium - high expectations embedded
Momentum
Strong
+18.4% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TLX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 19, 2026
Reported EPS of $0.11 vs $0.04 consensus (+140.3% surprise). Revenue of $477.0M vs $479.6M expected (-0.6%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+140.3%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 20, 2026
vs Industry
How TLX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.